Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Retained Earnings (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Retained Earnings data on record, last reported at -$81.2 million in Q3 2025.

  • For Q3 2025, Retained Earnings fell 33.58% year-over-year to -$81.2 million; the TTM value through Sep 2025 reached -$81.2 million, down 33.58%, while the annual FY2024 figure was -$247549.0, 200.12% down from the prior year.
  • Retained Earnings reached -$81.2 million in Q3 2025 per GANX's latest filing, roughly flat from -$81.2 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $247241.0 in Q4 2023 and bottomed at -$81.2 million in Q1 2025.
  • Average Retained Earnings over 5 years is -$25.9 million, with a median of -$296900.0 recorded in 2022.
  • Peak YoY movement for Retained Earnings: surged 593.97% in 2023, then plummeted 67145.79% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$7.0 million in 2021, then soared by 100.51% to $35627.0 in 2022, then soared by 593.97% to $247241.0 in 2023, then plummeted by 200.12% to -$247549.0 in 2024, then tumbled by 32699.53% to -$81.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$81.2 million in Q3 2025, -$81.2 million in Q2 2025, and -$81.2 million in Q1 2025.